Skip to main content

Table 3 Risk of pneumonia by type of treatment (FP, other ICS, no ICS use) at baseline

From: Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

 

Treatment at baseline

Comparison

FP

Other ICS

No ICS

FP versus other ICS

HR* or RR

(95% CI);

p-value

FP versus no ICS

HR* or RR

(95% CI);

p-value

Other ICS versus no ICS

HR* or RR

(95% CI);

p-value

Use at baseline, n

1334

1334

1334

Patients with pneumonia event, n (%)#

207 (15.5)

184 (13.8)

169 (12.7)

HR 1.20

(0.99, 1.47);

p = 0.067

HR 1.30

(1.06, 1.59);

p = 0.012

HR 1.08

(0.88, 1.33);

p = 0.467

Pneumonia events, n

286

220

214

Adjusted rate of pneumonia events (per patient-year), mean (95% CI)

0.10

(0.08, 0.12)

0.07

(0.06, 0.09)

0.07

(0.05, 0.09)

RR 1.35

(1.05, 1.74);

p = 0.020

RR 1.37

(1.06, 1.78);

p = 0.015

RR 1.02

(0.77, 1.34);

p = 0.907

Patients with hospitalized pneumonia events, n (%)

140 (10.5)

114 (8.5)

100 (7.5)

HR 1.31

(1.02, 1.68);

p = 0.032

HR 1.48

(1.14, 1.91);

p = 0.003

HR 1.13

(0.86, 1.47);

p = 0.382

Hospitalized pneumonia events, n

172

133

121

Adjusted rate of hospitalized pneumonia events (per patient-year), mean (95% CI)

0.06

(0.04, 0.08)

0.04

(0.03, 0.06)

0.04

(0.03, 0.05)

RR 1.34

(0.99, 1.81);

p = 0.055

RR 1.46

(1.07, 1.98);

p = 0.016

RR 1.09

(0.79, 1.51);

p = 0.607

Patients with pneumonia resulting in death, n (%)

8 (0.60)

18 (1.35)

15 (1.12)

HR 0.46

(0.20, 1.05);

p = 0.066

HR 0.55

(0.23, 1.30);

p = 0.174

HR 1.20

(0.61, 2.39);

p = 0.595

  1. Abbreviations: CI confidence interval, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, GOLD Global Initiative for Chronic Obstructive Lung Disease, HR hazard ratio, ICS inhaled corticosteroid, RR rate ratio. Matched-subgroup population. *Cox regression analysis with ICS use at baseline and matching factors as covariates. Poisson regression with ICS use at baseline and matching factors (age, FEV1% predicted, GOLD stage, emphysema diagnosis, and courses of antibiotics) as covariates. #32 patients treated with FP at baseline received this treatment for non-pulmonary (mostly nasal) indication only; four of these patients had a pneumonia event during the study. In the “other ICS” group, these numbers were 43 and 11, respectively